Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting

Rhea-AI Summary

Alkermes plc (Nasdaq: ALKS) announced the acceptance of two abstracts for the upcoming 2021 ASCO Annual Meeting from June 4-8, 2021, showcasing their investigational therapy, nemvaleukin alfa. The data will detail its efficacy and tolerability from the ARTISTRY-1 and ARTISTRY-2 clinical trials. The first abstract discusses nemvaleukin monotherapy and its combination with KEYTRUDA in advanced solid tumors, while the second focuses on selecting the recommended phase 2 dose for subcutaneous administration. These presentations represent critical steps in the development of new cancer therapies.

Positive

• Acceptance of two abstracts for presentation at a prestigious conference.
• Data from phase 1/2 ARTISTRY trials may validate the efficacy of nemvaleukin alfa.
• Potential to enhance Alkermes' product pipeline in oncology.

Negative

• None.

DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the acceptance of two abstracts related to nemvaleukin alfa (nemvaleukin), the company's novel, investigational engineered interleukin-2 (IL-2) variant immunotherapy, at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place virtually June 4-8, 2021. New data from the phase 1/2 ARTISTRY-1 clinical trial evaluating the tolerability and efficacy of nemvaleukin administered intravenously as a monotherapy and in combination with pembrolizumab (KEYTRUDA^®) will be shared in a poster discussion session. In addition, data supporting the recommended phase 2 dose (RP2D) for nemvaleukin administered subcutaneously from the phase 1/2 ARTISTRY-2 clinical trial will be shared in a separate poster.

Details of the presentations are as follows:
Abstract: 2513
Title: ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors
Presenter: Valentina Boni, M.D., Ph.D., Medical Oncologist and Principal Investigator, START Madrid at Centro Integral Oncológico Clara Campal
Presentation Date/Time: The on-demand poster discussion session will take place on June 4, 2021 from 9:00 – 10:00 a.m. ET.

Abstract: 2552
Title: Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2
Presenter: Omid Hamid, M.D., Chief of Research and Immunotherapy, The Angeles Clinic and Research Institute
Presentation Date: The poster presentation will be available on-demand to attendees beginning June 4, 2021.

About Nemvaleukin alfa ("nemvaleukin")
Nemvaleukin is an investigational, novel, engineered fusion protein comprised of modified interleukin-2 (IL-2) and the high affinity IL-2 alpha receptor chain, designed to selectively expand tumor-killing immune cells while avoiding the activation of immunosuppressive cells by preferentially binding to the intermediate-affinity IL-2 receptor complex. The selectivity of nemvaleukin is designed to leverage the proven anti-tumor effects of existing IL-2 therapy while mitigating certain limitations.

About the ARTISTRY Clinical Development Program 
ARTISTRY is an Alkermes-sponsored clinical development program evaluating nemvaleukin alfa as a potential immunotherapy for cancer. The ARTISTRY program is comprised of multiple clinical trials evaluating intravenous and subcutaneous dosing of nemvaleukin, both as a monotherapy and in combination with the anti-PD-1 therapy KEYTRUDA^® (pembrolizumab) in patients with advanced solid tumors. Ongoing trials include: ARTISTRY-1, ARTISTRY-2, ARTISTRY-3 and ARTISTRY-6.

About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction and schizophrenia, and a pipeline of product candidates in development for schizophrenia, bipolar I disorder, neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.

KEYTRUDA^® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

Alkermes Contacts: 
For Investors: Sandy Coombs, +1 781 609 6377
For Media: Sourojit Bhowmick, Ph.D. +1 781 609 6397

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-announces-two-abstracts-accepted-for-presentation-at-2021-american-society-of-clinical-oncology-annual-meeting-301278601.html

SOURCE Alkermes plc

FAQ

What are the abstracts presented by Alkermes at the 2021 ASCO Annual Meeting?

Alkermes is presenting two abstracts on nemvaleukin alfa, focusing on its efficacy as a monotherapy and in combination with KEYTRUDA.

When will Alkermes present its findings at the ASCO Annual Meeting?

The presentations will take place during the ASCO Annual Meeting from June 4-8, 2021.

What is nemvaleukin alfa and its relevance in cancer treatment?

Nemvaleukin alfa is an investigational IL-2 variant designed to enhance anti-tumor immunity while minimizing immunosuppressive effects.

How does the ARTISTRY clinical program benefit Alkermes?

The ARTISTRY program aims to evaluate nemvaleukin alfa's potential in cancer immunotherapy, potentially expanding Alkermes' oncology portfolio.

Where can I find more information about Alkermes' clinical trials?

Further details about Alkermes' clinical trials can be found on their website and clinical trial registries.